While not mandated today, the FDA has “strongly suggested” that participants in the drug supply chain deploy some means of electronically tracking drugs at the item level—preferably (again, not mandated) one utilizing RFID.
In addition to regulatory pressure, gray market and counterfeiting activities create incentives—both financial and patient safety related—for companies to efficiently authenticate items as well.
Once drugs have been tagged at the item level with serialized RFID tags, the same system can do both. |
